Novartis presents Cosentyx as a pioneer at EULAR 2019

12 June 2019

Novartis (NOVN: VX) has boasted that Cosentyx (secukinumab) has become the first drug to show efficacy in all key manifestations of psoriatic arthritis (PsA).

The Swiss pharma giant presented two new sets of data on Wednesday at the EULAR Congress in Madrid, Spain.

Results from the MAXIMISE trial evaluating the efficacy and safety of Cosentyx in the management of axial manifestations of PsA showed that 66.3% of patients treated with a 150mg dose achieved rapid and significant improvements in signs and symptoms of the illness at week 12.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK